长时间的QT和Tp-e间隔在男性药物滥用者:从横截面研究的见解
Yusuf Hoşoğlu1, Ahmet Doğru2, Ayşe Hoşoğlu3
1Department of Cardiology, Adıyaman University Training and Research Hospital, Adıyaman, Türkiye.
Cardiovascular journal of Africa
|February 20, 2026
概括
药物滥用与延长QT和纠正QT (QTc) 间隔有关,增加心律失常的风险. 修正后的Tp-e区间也可能表明物质使用者的再极化问题.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学 是一个学科.
- 公共卫生 公共卫生
背景情况:
- 药物滥用带来了相当大的心血管风险.
- 电心电图 (ECG) 参数,如QT和Tp-e间隔,对于评估心脏健康至关重要.
- 了解物质滥用对心电图参数的影响对于风险分层至关重要.
研究的目的:
- 调查药物滥用和心电图参数 (QT,QTc,Tp-e间隔) 之间的关联.
- 评估药物滥用者的潜在心律失常风险.
- 在这个人群中确定QT延长的预测因素.
主要方法:
- 一项横截面研究,将126名男性药物滥用者与126名对照者进行比较.
- 使用标准的12导电心电图来测量QT,使用Bazett和Friedrich方法纠正QT (QTc),以及Tp-e间隔.
- 进行了统计分析,包括多变量逻辑回归,以比较群体并确定风险因素.
主要成果:
- 与对照组相比,药物滥用者表现出明显延长的QT和QTc间隔.
- 甲基胺使用者具有最长的QTcB,其次是海洛因和合成大麻素使用者.
- 年龄,甲基胺使用,多种物质使用,以及特定物质使用的持续时间/频率预测QTc延长. 在药物滥用者中,修正的Tp-ec间隔较长.
结论:
- 药物滥用与延长的QT和QTc间隔有关,这表明心律不整的风险增加.
- 修正后的Tp-e间隔可能是药物滥用者复极异常的敏感标志物.
- 建议进行进一步的研究和临床警,以监测物质使用者的心血管风险.
相关概念视频
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
648
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
648
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
725
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
725
Pharmacodynamic Models: Linear Concentration–Effect Model
25
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
25
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
33
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
33
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
29
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
29
Drug Toxicity: Risk factors
38
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
38


